Funding for this research was provided by:
Foundation for the National Institutes of Health (Kidney Spore)
Received: 2 November 2017
Accepted: 3 January 2018
First Online: 22 January 2018
: Not applicable.
: The study was approved by the local institutional review boards and was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helskinki.
: Informed consent for publication has been obtained and the consent forms are held by the authors.
: AAL: honoraria/consulting from Novartis; conference travel expenses from Pfizer.WX: honoraria/consulting from Bayer.JB: honoraria/consulting from Astellas, Genentech, Merck, Novartis, Pfizer, Pierre Fabre; institutional research funding/support from Millenium, Sanofi, MSD Oncology, Pfizer.EMVA: honoraria/consulting from Genome Medical, Novartis, Roche, Syapse, Takeda, Third Rock Ventures; institutional research funding/support from Bristol-Myers Squibb, Novartis.BAM: honoraria/consulting from Astellas, Seattle Genetics, Bayer, Astra-Zeneca, Genentech and Exelixis.LCH: honoraria/consulting from Genentech, Pfizer, Dendreon, NCCN, Medivation/Astellas, KEW, Corvus, Merck; institutional research funding/support from Bayer, Medivation/Astellas, Pfizer, Dendreon, Sotio, Genentech, Merck, BMS, Jannsen.TKC: honoraria/consulting from Alligent, AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean Pharma, Eisai, Exelixis, Foundation Medicine, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus, Roche/Genentech; institutional research funding/support from Pfizer, Exelixis, Bristol-Myers Squibb, Novartis, Peloton, AstraZeneca, Agensys, TRACON.The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.